Display Settings:

Format
Sort by

Send to:

Choose Destination

    Results: 5

    1.

    Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: FIELD Helsinki Substudy.

    Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR.

    Diabetes Care. 2009 Oct 21. [Epub ahead of print]PMID: 19846798 [PubMed - as supplied by publisher]Related articles

    2.

    ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

    Hiukka A, Ståhlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Hultén LM, Wiklund O, Oresic M, Olofsson SO, Taskinen MR, Ekroos K, Borén J.

    Diabetes. 2009 Sep;58(9):2018-26. Epub 2009 Jun 5.PMID: 19502413 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

    Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Järvinen H, Keech AC, Taskinen MR.

    J Am Coll Cardiol. 2008 Dec 16;52(25):2190-7.PMID: 19095138 [PubMed - indexed for MEDLINE]Related articles

    4.

    Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.

    Leinonen ES, Hiukka A, Hurt-Camejo E, Wiklund O, Sarna SS, Mattson Hultén L, Westerbacka J, Salonen RM, Salonen JT, Taskinen MR.

    J Intern Med. 2004 Aug;256(2):119-27.PMID: 15257724 [PubMed - indexed for MEDLINE]Related articles

    5.

    Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.

    Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR.

    Diabetes Care. 2002 Oct;25(10):1807-12.PMID: 12351482 [PubMed - indexed for MEDLINE]Related articlesFree article